HB0017 vs UA026

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-17A · full Psoriasis pipeline

HB0017

Developed by Huabo Biopharm Co.

Phase 3 in Psoriasismonoclonal antibody
Partial signal

NCT06477237 · Phase 3 · completed

This is a randomized, quadruple-blind, placebo-controlled Phase 3 trial using validated psoriasis response measures as its primary endpoints, but no results are yet posted to the registry, so the outcome is unknown.

Next expected readout: December 2026 · NCT07920861 (registry estimate)

Reported efficacy

PASI 90 response (Week 12); sPGA 0/1 response (Week 12): Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens. (unclear)

Result source: NCT05531682

UA026

Developed by Usynova Pharmaceuticals Ltd.

Phase 1 in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHB0017UA026
PASI 75—Not posted · NCT06477237—Not reported
PASI 90—Not posted · NCT06477237—Not reported
PASI 100—Not posted · NCT06477237—Not reported
sPGA 0/1—Not posted · NCT06477237—Not reported
DLQI, change—Not posted · NCT06477237—Not reported

PASI 75

HB0017
—Not posted · NCT06477237
UA026
—Not reported

PASI 90

HB0017
—Not posted · NCT06477237
UA026
—Not reported

PASI 100

HB0017
—Not posted · NCT06477237
UA026
—Not reported

sPGA 0/1

HB0017
—Not posted · NCT06477237
UA026
—Not reported

DLQI, change

HB0017
—Not posted · NCT06477237
UA026
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

UA026: no structured comparison results are available for Psoriasis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HB0017
Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens. NCT05531682 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HB0017's landscape · UA026's landscape